Timely levodopa (LD) administration prolongs survival in Parkinson's disease.

[1]  D. Schroeder,et al.  Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.

[2]  E. van der Velde,et al.  Clinical course of patients with idiopathic Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.

[3]  N H Holford,et al.  The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.

[4]  M. Mena,et al.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants , 1995, Brain Research.

[5]  C. Clarke.  Does levodopa therapy delay death in Parkinson's disease? A review of the evidence , 1995, Movement disorders : official journal of the Movement Disorder Society.

[6]  T. Engber,et al.  Motor response complications and the function of striatal efferent systems , 1993, Neurology.

[7]  S. Fahn,et al.  Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity , 1993, Annals of neurology.

[8]  D. Maraganore,et al.  Levodopa therapy and survival in idiopathic Parkinson's disease , 1993, Neurology.

[9]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[10]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[11]  D. Perl,et al.  Two decades of increasing mortality from Parkinson's disease among the US elderly. , 1990, Archives of neurology.

[12]  M. Musicco,et al.  Mortality associated with early and late levodopa therapy initiation in Parkinson's disease , 1990, Neurology.

[13]  J. Kurtzke,et al.  The changing patterns of death rates in parkinsonism , 1990, Neurology.

[14]  C. Markham,et al.  Effect of age at onset on progression and mortality in Parkinson's disease , 1989, Neurology.

[15]  L. Golbe,et al.  Toward a definition of Parkinson's disease , 1989, Neurology.

[16]  R. Duvoisin.  To treat early or to treat late? , 1987, Annals of neurology.

[17]  M. Muenter,et al.  Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.

[18]  C. Markham,et al.  Long‐term follow‐up of early dopa treatment in Parkinson's disease , 1986, Annals of neurology.

[19]  Dallas W. Anderson,et al.  Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi , 1985, Neurology.

[20]  K P Offord,et al.  Epidemiology of parkinsonism: Incidence, classification, and mortality , 1984, Annals of neurology.

[21]  A. Rajput,et al.  Chronic low‐dose levodopa therapy in Parkinson's disease , 1984, Neurology.

[22]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[23]  C. Joseph,et al.  Levodopa in Parkinson disease: A long‐term appraisal of mortality , 1978, Annals of neurology.

[24]  R. Marttila,et al.  DEMENTIA IN PARKINSON'S DISEASE , 1976, Acta neurologica Scandinavica.

[25]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[26]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[27]  A. Barbeau.  The pathogenesis of Parkinson's disease: a new hypothesis. , 1962, Canadian Medical Association journal.

[28]  O. Hornykiewicz,et al.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  A. Rajput,et al.  Pulmonary embolism: An under‐recognized yet frequent cause of death in parkinsonism , 1994, Movement disorders : official journal of the Movement Disorder Society.

[31]  K. Mizukawa,et al.  Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.

[32]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[33]  R. Uitti,et al.  Neurological disorders and services in Saskatchewan--a report based on provincial health care records. , 1988, Neuroepidemiology.

[34]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[35]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[36]  D. Cox.  Regression Models and Life-Tables , 1972 .